Phibro Animal Health (PAHC) details quarterly results and 2026 fiscal guidance

Rhea-AI Filing Summary

Phibro Animal Health Corporation filed a Form 8-K stating that on February 4, 2026 it issued a press release announcing operating results for the fiscal quarter ended December 31, 2025 and financial guidance for the fiscal year ending June 30, 2026. The press release is furnished as Exhibit 99.1 and, along with the 8-K disclosure, is designated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

0001069899false00010698992026-02-042026-02-04

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

​

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 4, 2026

Phibro Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

​

Delaware	​ ​ ​	001-36410	​ ​ ​	13-1840497
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

Glenpointe Centre East, 3rd Floor

300 Frank W. Burr Boulevard, Suite 21

Teaneck, New Jersey 07666-6712

(Address of Principal Executive Offices, including Zip Code)

​

(201) 329-7300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	​	PAHC	​	NASDAQ Stock Market

​

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

ITEM 2.02     RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 4, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit Number	​ ​ ​	Description
99.1		Press Release, dated February 4, 2026
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​	PHIBRO ANIMAL HEALTH CORPORATION Registrant
​	​
Date: February 4, 2026	​
​	​
​	By:	/s/ Judith Weinstein
​	Name:	Judith Weinstein
​	Title:	Senior Vice President, General Counsel and Corporate Secretary

​

​

​

FAQ

What did Phibro Animal Health (PAHC) disclose in this Form 8-K?

Phibro Animal Health disclosed that it issued a press release announcing operating results for the fiscal quarter ended December 31, 2025 and provided financial guidance for the fiscal year ending June 30, 2026, with the release furnished as Exhibit 99.1.

Which period’s results does Phibro Animal Health (PAHC) address in the press release?

The press release addresses operating results for Phibro Animal Health’s fiscal quarter ended December 31, 2025. It also includes financial guidance for the company’s fiscal year ending June 30, 2026, according to the Form 8-K disclosure under the results of operations item.

How is the Phibro Animal Health (PAHC) earnings press release included in the 8-K?

The earnings press release is included as Exhibit 99.1 to the Form 8-K. The company states that this exhibit, and the related disclosure, are being furnished, not filed, under the Securities Exchange Act of 1934, limiting automatic incorporation into other filings.

Is the Phibro Animal Health (PAHC) earnings information considered “filed” with the SEC?

No. Phibro Animal Health specifies that the information in this report, including Exhibit 99.1, is being furnished and shall not be deemed filed under Section 18 of the Securities Exchange Act of 1934, nor incorporated into other filings unless expressly referenced.

What exhibits accompany Phibro Animal Health’s (PAHC) Form 8-K?

The Form 8-K lists two exhibits: Exhibit 99.1, which is the press release dated February 4, 2026, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document, as specified in the exhibits section.

Who signed the Phibro Animal Health (PAHC) Form 8-K and in what capacity?

The Form 8-K was signed on behalf of Phibro Animal Health Corporation by Judith Weinstein. She is identified in the filing as Senior Vice President, General Counsel and Corporate Secretary, indicating her authority to sign for the registrant.